Carlsmed CARL 2025Q2 Earnings Preview Upside Potential on AI-Driven Spine Solutions

Forward-Looking Analysis
Analysts expect Carlsmed to report Q2 2025 earnings after market close on August 28, 2025, with the company hosting a conference call at 1:30 PM PT. Current projections indicate an estimated revenue of $11.5 million, up from Q1’s $10.19 million. While net income is expected to remain in the red, EPS is forecasted at -$0.24, showing slight improvement from Q1’s -$0.26. Analysts have not issued recent upgrades or downgrades, and no price targets were reported. The focus remains on the company’s AI-enabled personalized spine surgery solutions driving long-term growth.

Historical Performance Review
In Q1 2025, Carlsmed reported revenue of $10.19 million and a net loss of $5.73 million, or $0.26 per share. Gross profit stood at $7.64 million. The company continues to operate at a loss but has shown revenue growth compared to prior periods, indicating potential for improved efficiency and product adoption in the AI-enabled spine surgery segment.

Additional News
Carlsmed is set to report Q2 2025 results on August 28, 2025, after market close, with a conference call and webcast scheduled at 1:30 PM PT. No major non-earnings news was reported recently. The stock gained 1.24% on a recent update. The company maintains a market cap of $332.78 million and an enterprise value of $306.43 million. No significant M&A or product launch announcements were noted.

Summary & Outlook
Carlsmed continues to operate at a loss but shows steady revenue growth, driven by its AI-enabled spine surgery solutions. While net income and EPS remain negative, the company is on a path of improving efficiency and product adoption. The key growth catalyst is the expansion of personalized AI-driven solutions in the medical technology space. With a strong market cap and upcoming earnings release, Carlsmed remains in a cautiously optimistic position for long-term investors.